Abstract:The COVID-19 pandemic is now approaching 2 years old, with more than 440 million people infected and nearly six million dead worldwide, making it the most significant pandemic since the 1918 influenza pandemic. The severity and significance of SARS-CoV-2 was recognized immediately upon discovery, leading to innumerable companies and institutes designing and generating vaccines and therapeutic antibodies literally as soon as recombinant SARS-CoV-2 spike protein sequence was available. Within months of the pandemic start, several antibodies had been generated, tested, and moved into clinical trials, including Eli Lilly's bamlanivimab and etesevimab, Regeneron's mixture of imdevimab and casirivimab, Vir's sotrovimab, Celltrion's regdanvimab, and Lilly's bebtelovimab. These antibodies all have now received at least Emergency Use Authorizations (EUAs) and some have received full approval in select countries. To date, more than three dozen antibodies or antibody combinations have been forwarded into clinical trials. These antibodies to SARS-CoV-2 all target the receptor-binding domain (RBD), with some blocking the ability of the RBD to bind human ACE2, while others bind core regions of the RBD to modulate spike stability or ability to fuse to host cell membranes. While these antibodies were being discovered and developed, new variants of SARS-CoV-2 have cropped up in real time, altering the antibody landscape on a moving basis. Over the past year, the search has widened to find antibodies capable of neutralizing the wide array of variants that have arisen, including Alpha, Beta, Gamma, Delta, and Omicron. The recent rise and dominance of the Omicron family of variants, including the rather disparate BA.1 and BA.2 variants, demonstrate the need to continue to find new approaches to neutralize the rapidly evolving SARS-CoV-2 virus. This review highlights both convalescent plasma- and polyclonal antibody-based approaches as well as the top approximately 50 antibodies to SARS-CoV-2, their epitopes, their ability to bind to SARS-CoV-2 variants, and how they are delivered. New approaches to antibody constructs, including single domain antibodies, bispecific antibodies, IgA- and IgM-based antibodies, and modified ACE2-Fc fusion proteins, are also described. Finally, antibodies being developed for palliative care of COVID-19 disease, including the ramifications of cytokine release syndrome (CRS) and acute respiratory distress syndrome (ARDS), are described.

Therapeutic antibodies and alternative formats against SARS-CoV-2

Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants

Therapeutic antibodies under development for SARS-CoV-2

A Review of the Currently Available Antibody Therapy for the Treatment of Coronavirus Disease 2019 (COVID-19)

Review of COVID-19 Antibody Therapies

Antibody-Based Immunotherapeutic Strategies for COVID-19

The development of biologics to target SARS-CoV2: Treatment potential of antibodies in patient groups with poor immune response

From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2

Advancements in the Development of Anti-SARS-CoV-2 Therapeutics

A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies

Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19

Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses

Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects

The development of neutralizing antibodies against SARS-CoV-2 and their common features

SARS-CoV-2 Omicron: Viral Evolution, Immune Evasion, and Alternative Durable Therapeutic Strategies

Recent advances in vaccine and immunotherapy for COVID-19

Anti-SARS-CoV-2 Vaccines and Monoclonal Antibodies Facing Viral Variants

Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review)

Aptamers Targeting SARS-COV-2: a Promising Tool to Fight Against COVID-19.

Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic